DOI: http://dx.doi.org/10.18203/2349-3291.ijcp20194768

Sulfonamides: far from obsolete

Mahmoud Moussa Hassanein

Abstract


Sulfa drugs or sulfonamides were introduced in 1935 by the German physician Gerhard Domagk (1895-1964). Domagk worked closely with two chemists, Fritz Mietzsch and Josef Klarer. They worked together on compounds related to synthetic dyes, testing their effects on infectious diseases. Their concerted work eventually led to the discovery of Prontosil (sulfamidochrysoidine), the first sulfa drug that showed an incredible antibacterial effect on diseased laboratory mice. Soon after the introduction of sulfonamides, penicillin was discovered and hailed as a more effective and a safer alternative. The production of sulfonamides lost its enthusiasm with the introductions of even more antibiotics. However; anti-bacterial Sulfonamides are far from being obsolete despite the introduction of newer classes of antibiotics. Interest in their use has been revived in the 1980s with AIDS epidemic, when a combination of sulfamethoxazole and trimethoprim (SMX/TMP) was recognized as the drug of choice for the treatment of Pneumocystis jirovecii (PCP) pneumonia. This review article is intended to update clinicians with the many still current recommendations for sulfonamides both as therapeutic and prophylactic agents; with mechanism of action and resistance; and with adverse side effects that clinicians need to watch for while using this class of antimicrobial.


Keywords


Adverse reactions to sulfonamides, Diaminopyrimidines, Drug resistance to sulfonamides, Glimpse of history of sulfa drugs, Mechanism of action of sulphonamides, Sulfonamides

Full Text:

PDF

References


Domagk G. Ein beitrag zur chemotherapie der bakteriellen infektionen. DMW-Deutsche Medizinische Wochenschrift. 1935 Feb;61(07):250-3.

Fourneau E, Trefouel J, Tréfouël J, Nitti F, Bovet D. Chimiothérapie des infections streptococciques par les dérivés du p-aminophénylsulfamide. Compt Rend Soc De Biol. 1936;122(258):652-4.

Henry Masur. Prevention and Treatment of Pneumocystis pneumonia. N Engl J Med. 1992;327:1853-60.

Sköld O. Sulfonamide resistance: mechanisms and trends. Drug Resist Updates. 2000 Jun 1;3(3):155-60.

Hein R, Brunkhorst R, Thon WF, Schedel I, Schmidt RE. Symptomatic sulfadiazine crystalluria in AIDS patients: a report of two cases. Clini Nephrol. 1993 May;39(5):254-6.

Kishore D, Pareek A. Short review on sulfonamides. Internat J Pharma Biosci. 2013;4:812-20.

Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: Recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Available at: http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf. Accessed on 26 April 2018.

Liu C. Infectious Diseases Society of America. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52:e18-55.

Hall H, Gadhok R, Alshafi K, Bilton D, Simmonds NJ. Eradication of respiratory tract MRSA at a large adult cystic fibrosis centre. Respirat Medi. 2015 Mar 1;109(3):357-63.

Schooley RT, Clumeck N, Haubrich R, Thompson M, Danner SA, van Der Ende ME, et al. A dose-ranging study to evaluate the antiretroviral activity and safety of amprenavir alone and in combination with abacavir in HIV-infected adults with limited antiretroviral experience. Antiviral Ther. 2001 Jun 1;6(2):89-96.

Molina JM, Ait-Khaled M, Rinaldi R, Penco G, Baril JG, Cauda R, et al. Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance. J Antimicrob Chemother. 2009 Jun 10;64(2):398-410.

Craig JC, Simpson JM, Williams GJ, Lowe A, Reynolds GJ, McTaggart SJ, et al. Antibiotic prophylaxis and recurrent urinary tract infection in children. New Eng J Medi. 2009 Oct 29;361(18):1748-59.

RIVUR Trial Investigators. Antimicrobial prophylaxis for children with vesicoureteral reflux. New Engl J Medi. 2014 Jun 19;370(25):2367-76.

Hassani AS, Marston BJ, Kaplan JE. Assessment of the impact of cotrimoxazole prophylaxis on key outcomes among HIV-infected adults in low-and middle-income countries: a systematic review. J Acquir Immune Defic Synd-(1999). 2015 Apr 15;68(Suppl 3):S257.

Margolis DM, Melnick DA, Ailing DW, Gallin JI. Trimethoprim-sulfamethoxazole prophylaxis in the management of chronic granulomatous disease. J Infect Dis. 1990 Sep 1;162(3):723-6.

Hedberg ST, Fredlund H, Nicolas P, Caugant DA, Olcén P, Unemo M. Antibiotic susceptibility and characteristics of Neisseria meningitidis isolates from the African meningitis belt, 2000 to 2006: phenotypic and genotypic perspectives. Antimicro Agent Chemother. 2009;53(4):1561-6.

Rex JH, Walsh TJ, Sobel JD, Filler SG, Pappas PG, Dismukes WE, et al. Practice guidelines for the treatment of candidiasis. Clini Infect Dis. 2000 Apr 1;30(4):662-78.

Lesch JE. The first miracle drugs: how the sulfa drugs transformed medicine. Oxford Uni Press. USA; 2007.

Hammoudeh DI, Zhao Y, White SW, Lee RE. Replacing sulfa drugs with novel DHPS inhibitors. Future Medi Chem. 2013 Jul;5(11):1331-40.